Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2729Lung Neoplasms 945Small Cell Lung Carcinoma 447Neoplasms 419Colorectal Neoplasms 409Breast Neoplasms 355Melanoma 332Ovarian Neoplasms 316Neoplasm Metastasis 281Pancreatic Neoplasms 252Squamous Cell Carcinoma of Head and Neck 232Stomach Neoplasms 227Carcinoma, Renal Cell 214Triple Negative Breast Neoplasms 190Head and Neck Neoplasms 178Prostatic Neoplasms 152Esophageal Neoplasms 149Endometrial Neoplasms 145Uterine Cervical Neoplasms 139Urinary Bladder Neoplasms 132Mesothelioma 115Carcinoma 106Colonic Neoplasms 104Carcinoma, Hepatocellular 104Sarcoma 99Carcinoma, Transitional Cell 99Kidney Neoplasms 74Mesothelioma, Malignant 72Cholangiocarcinoma 67Liver Neoplasms 66

Interventions

brigatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × ALK-positive Advanced NSCLC × Thoracic × Clear all
NCT03535740 2025-07-31

ALTA-2

Takeda

Phase 2 Completed
103 enrolled 23 charts
Thoracic

ALK-positive Advanced NSCLC

NCT03410108 2024-05-08

Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

Takeda

Phase 2 Completed
104 enrolled 22 charts
Thoracic

ALK-positive Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡